Loading…
Journey Medical Corp
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in DERM.
▼ -22.4% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $7.71 | $3.91 | $5.76 | $1.92 | $5.38 | |
| P/S | 1.3x | 3.1x | 1.4x | 1.3x | 0.5x | 0.9x |
| P/B | 4.0x | 5.9x | 4.0x | 5.2x | 2.0x | 1.3x |
| EPS | -$0.47 | -$0.72 | -$0.21 | -$1.69 | -$4.32 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ABOSAcumen Pharmaceuticals, Inc. | $2.92 | — | 3.7x | — | -120.50% | $211.17M |
| NKTXNkarta, Inc. | $2.95 | — | 0.9x | — | -38.76% | $211.29M |
| ORMPOramed Pharmaceuticals Inc | $5.03 | 1.2x | 0.7x | 4.97% | 74.24% | $209.23M |
| NBPNovaBridge Biosciences | $1.84 |
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Company description provided by Yahoo Finance.
| Profit margin | -26.14% | -18.48% | -26.14% | -4.87% | -40.22% | -69.68% |
| ROE | -73.11% | -35.89% | -73.11% | -18.93% | -174.47% | -104.64% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.1x |
| — |
| -59.10% |
| $212.79M |
| CNTNCanton Strategic Holdings, Inc. | $2.69 | — | 0.5x | — | -42.21% | $214.34M |
| PEPGPepGen Inc. | $2.98 | — | 1.7x | — | -75.45% | $206.12M |